Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Cancer Immunology, Immunotherapy : CII|October 11, 2005
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patientsLorenzo Pilla, Roberto Patuzzo, Licia Rivoltini, et al.
The New England Journal of Medicine|September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated MelanomaGeorgina V Long, Axel Hauschild, Mario Santinami, et al.
The Lancet. Oncology|April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trialDirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III MelanomaAxel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.
Nature Immunology|April 27, 2021
Heme catabolism by tumor-associated macrophages controls metastasis formationFrancesca Maria Consonni, Augusto Bleve, Maria Grazia Totaro, et al.
The New England Journal of Medicine|June 20, 2024
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaGeorgina V Long, Axel Hauschild, Mario Santinami, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 18, 2022
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapyAndrea Anichini, Alessandra Molla, Gabriella Nicolini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptidesPaola Filipazzi, Lorenzo Pilla, Luigi Mariani, et al.
Cell Communication and Signaling : CCS|September 24, 2020
miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediatorsElisabetta Vergani, Matteo Dugo, Mara Cossa, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2023
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanomaRachel S Goodman, Lorenza Di Guardo, Andrea Maurichi, et al.
Pageof 11